Dimerization of sumatriptan as an efficient way to design a potent, centrally and orally active 5-HT(1B) agonist

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 6, 1998, Pages 675-680

  Perez, Michel ^a   Pauwels, Petrus J ^a   Fourrier, Catherine ^a   Chopin, Philippe ^a   Valentin, Jean Pierre ^a   John, Gareth W ^a   Marien, M ^a   Halazy, Serge ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RECEPTOR SUBTYPE; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN RECEPTOR; SUMATRIPTAN; ZOLMITRIPTAN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIMERIZATION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; GUINEA PIG; HUMAN; HUMAN CELL; HYPOTHERMIA; NONHUMAN; RABBIT; RAT; SAPHENOUS VEIN; VASOCONSTRICTION;

ANIMALS; CELL LINE; DIMERIZATION; DRUG DESIGN; GUINEA PIGS; HUMANS; MODELS, CHEMICAL; RABBITS; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SUMATRIPTAN;

ANIMALIA; CAVIA PORCELLUS; ORYCTOLAGUS CUNICULUS; SUS SCROFA;

EID: 0032539780     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00090-0     Document Type: Article

References (22)

1. 1 Ferrari, M. D.; Saxena, P. R. Cephalagia 1993, 13, 151.
2. 2 Silberstein, S. D. Headache 1994, 408.
3. 3 Feniuk, W.; Humphrey, P. P. A. Drug Dev. Res. 1992, 26, 235.
4. 4 Zolmitriptan Drugs of the future 1997, 22, 260.
5. 5 MK-0462 Drugs of the future 1995, 20, 676.
6. 6 Connor, H. E.; Feniuk, W.; Beattie, D. T.; North, P. C.; Oxford, A. W.; Saynor, D. A.; Humphrey, P. P. A. Cephalagia 1997, 17, 145.
7. 7 Eletriptan Drugs of the future 1997, 22, 221.
8. 8 Goadsby, P. J.; Edvinsson, L. Headache 1994, 34, 394.
9. 9 Mills, A.; Martin, G. R. Eur. J. Pharmacol 1995, 280, 175.
10. 10 Martin, G. R. Eur. Neurol. 1996, 36, 13.
11. 11 Halazy, S.; Perez, M.; Fourrier, C.; Pallard, I.; Pauwels, P. J.; Palmier, C.; John, G. W.; Valentin, J.-P.; Bonnafous, R.; Martinez, J. J. Med. Chem. 1996, 39, 4920.
12. 12 Le Boulluec, K.; Mattson, R. J.; Mable, C. D.; Mc Govern, R. T.; Nowak, H. P.; Gentile, A. J. Bioorg. Med. Chem. Lett. 1995, 5, 123.
13. 2O) Calc. (%) C 54.57; H 6.76; N 10.48; Cl 9.05 Found (%) C 54.53; H 6.74; N 10.60; Cl 8.94
14. 14 Pauwels, P. J.; Palmier, C.; Colpaert, F. C. Cell. Pharmacol. 1995, 2, 49.
15. 15 Pauwels, P. J.; Van Gompel, P.; Leysen, J. E. Biochem. Pharmacol. 1993, 45, 375.
16. 16 Valentin, J.-P.; Bonnafous, R.; John, G. W. Br. J. Pharmacol. 1996, 119, 35.
17. 17 Skingle, M.; Higgins, G. A.; Feniuk, W. J. Psychopharmacol. 1994, 8, 14.
18. 18 Hatcher, J.-P.; Slade, P. D.; Roberts, C.; Hagan, J. J. J. Psychopharmacol. 1995, 9, 234.
19. 19 Perez, M.; Fourrier, C.; Sigogneau, I.; Pauwels, P. J.; Palmier, C.; John, G. W.; Valentin, J.-P.; Halazy, S J. Med. Chem. 1995, 38, 3602.
20. 20 Jorand-Lebrun, C.; Pauwels, P. J.; Palmier, C.; Moret, C.; Chopin, P.; Perez, M.; Marien, M.; Halazy, S. J. Med. Chem. 1997, 40, 3974.
21. 21 Hagan, J. J.; Slade, P. D.; Gaster, L.; Jeffrey, P.; Hatcher, J.-P.; Middlemiss, D. N. Eur. J. Pharmacol 1997, 331, 169.
22. 22 Goadsby, P. J.; Knight, Y. E. Cephalagia 1997,17, 153.